Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Infant Bacterial Therapeutics AB (IBT B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8135
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm City, Sweden.

Infant Bacterial Therapeutics AB (IBT B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Equity Offering 11
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 11
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 13
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 15
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 16
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 17
Infant Bacterial Therapeutics AB – Key Competitors 18
Infant Bacterial Therapeutics AB – Key Employees 19
Infant Bacterial Therapeutics AB – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Aug 28, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – June 30, 2017 21
May 04, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – March 31, 2017 24
Feb 14, 2017: Infant Bacterial Therapeutics Interim report January 1 – December 31 2016 25
Corporate Communications 26
May 09, 2018: Infant Bacterial Therapeutics Nomination Committee modifies its proposal to the Board of Directors 26
Mar 10, 2017: InfantBacterial Therapeutics has been approved for listing on Nasdaq First North’s Premier segment 27
Product News 28
Jun 26, 2018: IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO 28
Clinical Trials 29
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups 29
Jan 24, 2017: Last patient enrolled in IBT’s Phase 2 study 30
Other Significant Developments 31
Aug 16, 2018: Infant Bacterial Therapeutics interim management statement, January 1 – June 30, 2018 31
Feb 28, 2018: Infant Bacterial Therapeutics Interim Management Statement, January 1 – December 31, 2017 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 11
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 13
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 15
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 16
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 17
Infant Bacterial Therapeutics AB, Key Competitors 18
Infant Bacterial Therapeutics AB, Key Employees 19
Infant Bacterial Therapeutics AB, Subsidiaries 20

List of Figures
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • One Medical Group Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary One Medical Group Inc (One Medical) is a provider of medical and technology-enabled health care services. The company’s service offerings include primary and pediatric care, prenatal and women's health, nutrition and sports medicine, LGBT care, mental health, dermatology, family and integrat …
  • Neiman Marcus Group LTD LLC:戦略・SWOT・企業財務分析
    Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report Summary Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Georgia Power Co:企業の発電所・SWOT分析2018
    Georgia Power Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Blue Moon Zinc Corp.:企業の戦略・SWOT・財務情報
    Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report Summary Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Staples, Inc.:企業の戦略・SWOT・財務分析
    Staples, Inc. - Strategy, SWOT and Corporate Finance Report Summary Staples, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Cyclacel Pharmaceuticals Inc (CYCC):企業の財務・戦略的SWOT分析
    Cyclacel Pharmaceuticals Inc (CYCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Exonate Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs, which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The company’s alternative mRNA splicing is modulated in disease states that results in the pathologic …
  • gategroup Holding AG:企業の戦略・SWOT・財務分析
    gategroup Holding AG - Strategy, SWOT and Corporate Finance Report Summary gategroup Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Oasis Petroleum Inc (OAS):石油・ガス:M&Aディール及び事業提携情報
    Summary Oasis Petroleum Inc. (Oasis Petroleum) is an independent exploration and production company. It focuses on the acquisition and development of unconventional oil and natural gas resources. The company operates in the Williston Basin in North Dakota and Montana and Permian Basin. The company f …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Pacific Scientific Energetic Materials Company:企業の戦略・SWOT・財務分析
    Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report Summary Pacific Scientific Energetic Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Black Stone Minerals LP (BSM):石油・ガス:M&Aディール及び事業提携情報
    Summary Black Stone Minerals LP (Black Stone) is a mining and minerals exploration and development company that explores and produces mineral deposits. The company's services include participating on a working interest basis when economics are favorable, leasing minerals to exploration and productio …
  • Petrofac Ltd (PFC):企業の財務・戦略的SWOT分析
    Petrofac Ltd (PFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Steward Health Care System LLC:企業の戦略的SWOT分析
    Steward Health Care System LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • HCP Inc (HCP):企業の財務・戦略的SWOT分析
    HCP Inc (HCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • JinkoSolar Holding Co Ltd (JKS):電力:M&Aディール及び事業提携情報
    Summary JinkoSolar Holding Co Ltd (JinkoSolar) is a manufacturer of solar products. The company is involved in manufacturing and marketing of solar power products such as silicon ingots, silicon wafers, solar modules, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. …
  • Damas International Ltd:企業の戦略・SWOT・財務分析
    Damas International Ltd - Strategy, SWOT and Corporate Finance Report Summary Damas International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Molecular Partners AG (MOLN):企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and …
  • Camurus AB (CAMX):企業の財務・戦略的SWOT分析
    Summary Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s technology includes smart and versatile drug delivery, injection depot, …
  • Henkel AG & Co. KGaA:企業の戦略・SWOT・財務情報
    Henkel AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary Henkel AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆